Non-alcoholic steatohepatitis and iron: Increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis

Journal of Hepatology

Volumn 31, Issue 3, 1999, Pages 421-429

  Bonkovsky, Herbert L ^a,b,c   Jawaid, Qaiser ^a,b,c   Tortorelli, Kristina ^a,b,c   LeClair, Paula ^a,b,c   Cobb, Joseph ^a,b,c   Lambrecht, Richard W ^a,b,c   Banner, Barbara F ^a,c  

^a Department of Medicine ^*  (United States)

^b Ctr Stud Disorders of IPM   (United States)

^c University of Massachusetts   (United States)

Author keywords

Hemochromatosis; Hepatic fibrosis; HFE gene; Iron; Iron overload; Mutational analyses; Non alcoholic steatohepatitis; Oxidative stress; Pathogenesis; Restriction fragment length polymorphism(s)

Indexed keywords

ADULT; ARTICLE; FATTY LIVER; FEMALE; GENE MUTATION; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; GENOTYPE; HEMOCHROMATOSIS; HUMAN; IRON METABOLISM; IRON OVERLOAD; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

EID: 0033198317     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(99)80032-4     Document Type: Article

References (38)

1. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 107:1994;1103-1109.
2. James OF, Day CP. Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol. 29:1998;495-501.
3. Bonkovsky HL, Banner BF, Lambrecht RW, Rubin RB. Iron in liver diseases other than hemochromatosis. Semin Liver Dis. 16:1996;65-82.
4. Tavill AS. Hemochromatosis. Schiff L, Schiff ER, . Diseases of the Liver, 7th ed. 1993;669-691 JB Lippincott, Philadelphia.
5. Bacon BR, Tavill AS. Hemochromatosis and the iron overload syndromes. Zakim D, Boyer TD, . Hepatology. A Textbook of Liver Disease, 2nd ed. 1996;1444-1445 Saunders, Philadelphia.
6. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al. A novel MHC class I-like gene is mutated in patients with hereditary hemochromatosis. Nat Genet. 13:1996;399-408.
7. Bonkovsky HL. Disorders of iron overload-clinical. Bloomer JR, Goodman ZD, Ishak KG, . Clinical and Pathological Correlations in Liver Disease: Approaching the Next Millennium. 1998;303-329 The Armed Forces Institute of Pathology, Washington, DC.
8. Worwood M. Haemochromatosis. Clin Lab Haematol. 20:1998;65-75.
9. Beutler E, Gelbart T, West C, Lee P, Adams M, Blackstone R, et al. Mutation analysis in hereditary hemochromatosis. Blood Cells Mol Dis. 22:1996;187-194.
10. Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N, Obando J, DiBisceglie A, Tattrie C, et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology. 27:1998;1661-1669.
11. Roberts AG, Whatley SD, Morgan RR, Worwood M, Elder GH. Increased frequency of the hemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. Lancet. 349:1997;321-323.
12. Sampietro M, Piperno A, Lupica L, Arosio C, Vergani A, Corbetta N, et al. High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda. Hepatology. 27:1998;181-184.
13. Jawaid Q, LeClair P, Tortorelli K, Cobb J, Lambrecht RW, Bonkovsky HL. Non-alcoholic steatohepatitis (NASH) and hereditary hemochromatosis (HHC). [abstract] Gastroenterology. 114:1998;1264A.
14. Goodman Z, Non-Alcoholic Steatohepatitis Working Group . Abstracts of a Symposium presented by National Institute of Diabetes and Digestive and Kidney Disease. National Institute of Health and the Office of Research on Women's Health-OD. December, 1998;30. Bethesda, MD.
15. MacSween RNM, Anthony PP, Scheuer PJ. Pathology of the Liver. 1987;185 Churchill Livingstone, Edinburgh.
16. George DK, Goldwurm S, MacDonald GA, Cowley LL, Walker NI, Ward PJ, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology. 114:1998;311-318.
17. Moirand R, Mortaji AM, Loreal O, Paillard F, Brissot P, Deugnier Y. A new syndrome of liver iron overload with normal transferrin saturation. Lancet. 349:1997;95-97.
18. Deugnier Y, Moirand R, Jouanolle AM, LeGall JY, Brissot P, David V. HLA-H mutations in patients with iron overload and normal transferrin saturation. [abstract] Hepatology. 26:1997;199A.
19. Mendler MH, Moirand R, Turlin B, Sapey T, Guyader D, Brissot P, et al. Study of HFE mutations in the"dysmetabolic iron overload syndrome" [abstract] Hepatology. 28:1998;419A.
20. Szarvas F. Andrologic anomalies in various gastrointestinal diseases. Z Gesamte Inn Med. 38:1983;429-431.
21. Bothwell TH, Charlton RW, Motulsky AG. Idiopathic hemochromatosis. Stanbury JB, Wyngaarden JB, Fredrickson DS, Goldstein JL, Brown MS, . The Metabolic Basis of Inherited Disease, 5th ed. 1983;1275 McGraw-Hill, New York.
22. Stuart KA, Busfield F, Jazwinski C, Gibson P, Butterworth L, Cooksley WG, et al. The C282Y mutation in the haemochromatosis gene (HFE) and hepatitis C virus infection are independent cofactors for porphyria cutanea tarda in Australian patients. J Hepatol. 28:1998;404-409.
23. Raucy JL, Lasker JM, Kraner JC, Salazar DE, Leiber CS, Corcoran GB. Induction of cytochrome P450IIE1 in the obese overfed rat. Mol Pharmacol. 39:1991;275-280.
24. Weltman MD, Farrell GC, Liddle C. Increased hepatocyte CYP2E1 expression in a rat model of hepatic steatosis with inflammation. Gastroenterology. 111:1996;1645-1653.
25. Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology. 27:1998;128-133.
26. Leclercq I, Horsmans Y, Desager JP, Delzenne N, Geubel AP. Reduction in hepatic cytochrome P-450 is correlated to the degree of liver fat content in animal models of steatosis in the absence of inflammation. J Hepatol. 28:1998;410-416.
27. Bonkowsky HL, Sinclair PR, Sinclair JF. Hepatic heme metabolism and its control. Yale J Biol Med. 52:1979;13-37.
28. Tsukamoto H, Horne W, Kamimura S, Niemela O, Parkkila S, Yla-Herttuala S. Experimental liver cirrhosis induced by alcohol and iron. J Clin Invest. 96:1995;620-630.
29. Banner BF, Karamitsios N, Smith L, Bonkovsky HL. Enhanced phenotypic expression of alpha-1-antitrypsin deficiency in an MZ heterozygote with chronic hepatitis C. Am J Gastroent. 93:1998;1541-1545.
30. Doberneck RC, Nunn DB, Johnson DG, Conn HO. Iron metabolism after portacaval shunt in dogs. Arch Surg. 87:1963;741-743.
31. Conn HO. Portacaval anastomosis and hepatic hemosiderin deposition: a prospective, controlled investigation. Gastroenterology. 62:1972;61-72.
32. Cotler SJ, Bronner MP, Press RD, Carlson TH, Perkins JD, Emond MJ, et al. End-stage liver disease without hemochromatosis associated with elevated hepatic iron index. J Hepatol. 29:1998;257-262.
33. Shepherd PR, Soos MA, Siddle K. Inhibitors of phosphoinositide 3-kinase block exocytosis but not endocytosis of transferrin receptors in 3T3-L1 adipocytes. Biochem Biophys Res Commun. 211:1995;535-539.
34. Parkkila S, Waheed A, Britton RS, Bacon BR, Zhou XY, Tomatsu S, et al. Association of the transferrin receptor in human placenta with HFE, the protein defective in hereditary hemochromatosis. Proc Natl Acad Sci USA. 94:(13):1997;198-202.
35. Gross CN, Irrinki A, Feder JN, Enns CA. Co-trafficking of HFE, a nonclassical major histocompatibility complex class I protein, with the transferrin receptor implies a role in intracellular iron regulation. J Biol Chem. 273:(22):1998;068-074.
36. 2-microglobulin interaction and cell surface expression. J Biol Chem. 272:1997;14025-14028.
37. Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatology. 25:1997;759-768.
38. Hayashi H, Wakusawa S, Takikawa T, Ikeda R, Yano M, Yoshioka K. Long-term effect of iron removal on chronic hepatitis C. [abstract] Hepatology. 26:1997;215A.